A Phase 2 interventional study of Part 1, JM-010 component Group A and Part 1, JM-010 component Group B in Dyskinesias and Parkinson Disease, sponsored by Bukwang Pharmaceutical. Terminated at 2 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-06-17.
Sponsored by Bukwang Pharmaceutical · Phase 2, Interventional, and Treatment
This is a two-part, double-blind, placebo-controlled, randomized, multicenter Phase 2 clinical trial of JM-010 in patients with Parkinson's Disease.
This is a two-part, Phase 2, double-blind, placebo-controlled, randomized, multicentre study.
Subjects with a diagnosis of PD and dyskinesias in PD will complete a Screening Visit to assess eligibility to participate in the study.
179 studies on the registry are indexed under Dyskinesias; 24 are open to participants now.
This study's enrollment of 41 is above the median of 36 across 139 interventional studies indexed under Dyskinesias.
Browse Dyskinesias studies →Bukwang Pharmaceutical is the lead sponsor of 34 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other criteria related to other medical conditions to be referred to the protocol.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part 1, JM-010 component Group A
Drug: Part 1, JM-010 component Group A
Part 1, JM-010 component Group B
Drug: Part 1, JM-010 component Group B
Part 1, JM-010 component Group C
Drug: Part 1, JM-010 component Group C
Part 1, Placebo Group
Drug: Part 1, Placebo Group
Part 2, JM-010 combination Group A
Drug: Part 2, JM-010 combination Group A
Part 2, JM-010 combination Group B
Drug: Part 2, JM-010 combination Group B
Part 2, JM-010 component Group C
Drug: Part 2, JM-010 component Group C
Part 2, Placebo Group
Drug: Part 2, Placebo Group
JM-010 component Group A
JM-010 component Group B
JM-010 component Group C
Placebo Group
JM-010 combination Group A
JM-010 combination Group B
JM-010 component Group C
Placebo Group
Unified Dyskinesia Rating Scale (UDysRS)
Unified Dyskinesia Rating Scale (Scoring range: 0-104), higher score indicates more severe dyskinesia
Time frame: Week 12
Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
Movement Disorder Society Unified Parkinson's Disease Rating Scale (Part III Scoring range: 0-137), higher score indicates more severe motor impairment
Time frame: Week 12
Plan to share: No
No publications or documents are linked to this record.
This study is terminated, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.